• Adeno-associated viral vectors offer the potential of a one-time treatment targeting mutant genes or disease-critical pathways
• Delivery of any genetic medicines to the brain must address multiple challenges. This presentation will address issues of target choice, cell-specific expression, entry across the blood/CSF-brain barriers and dose-related toxicity for AAV capsids

NEW DATA